Department of Medicine (Geriatrics), Dalhousie University, Halifax, Nova Scotia, Canada.
Nova Scotia Health, Halifax, Nova Scotia, Canada.
BMC Geriatr. 2021 May 8;21(1):297. doi: 10.1186/s12877-021-02246-2.
Prescribing cascades are a source of inappropriate prescribing for older adults with dementia. We aimed to study three prescribing cascades in older Nova Scotians with dementia using administrative databases.
Cohort entry for Nova Scotia Seniors' Pharmacare Program beneficiaries was the date of dementia diagnosis. Prescription drug dispensing data was extracted for inciting medication and second treatment (cholinesterase inhibitor and bladder anticholinergic, metoclopramide and Parkinson's disease medication, or calcium channel blocker (CCB) and diuretic) over the six-year period April 1, 2009 to March 31, 2015. In three separate analyses, dispensing an inciting medication signaled a look back of 365 days from the date of first dispensing to confirm that the second treatment was started after the inciting medication. The prescribing cascade was considered when the second treatment was started within 180 days of the inciting treatment. Sex differences in the prescribing cascade were tested using t-tests or chi square tests as appropriate. Both univariate (unadjusted) and multivariate (adjusted) logistic regression (adjusted for age, rurality, and sex) and Cox proportional hazards regression was used to identify risk factors for the prescribing cascade.
From March 1, 2005 to March 31, 2015, 28,953 Nova Scotia Seniors' Pharmacare beneficiaries with dementia (NSSPBD) were identified. There were 60 cases of bladder anticholinergics following cholinesterase inhibitors, 11 cases of Parkinson's disease medication following metoclopramide, and 289 cases of a diuretic following CCB in the cohort. Regression analysis demonstrated that risk of bladder anticholinergics following cholinesterase inhibitors and diuretics following CCBs were associated with female sex. Cox regression suggested that bladder anticholinergics were less often used by those on cholinesterase inhibitors and did not identify CCB use as leading more frequently to diuretic use.
The combination of diuretics following CCB was the most common prescribing cascade and bladder anticholinergics following cholinesterase inhibitors the second most common. However, exposure to the inciting medications did not increase risk of exposure to the second treatments. Combinations of bladder anticholinergics following cholinesterase inhibitors and diuretics following CCBs were more common for women raising concern that women may be at increased risk of these prescribing cascades.
处方级联是导致老年痴呆症患者用药不当的一个原因。我们旨在使用行政数据库研究新斯科舍省老年痴呆症患者的三种处方级联。
新斯科舍省老年人处方药计划受益人的队列进入日期是痴呆症诊断日期。从 2009 年 4 月 1 日至 2015 年 3 月 31 日的六年期间,提取了引发药物和第二治疗药物(胆碱酯酶抑制剂和膀胱抗胆碱能药物、甲氧氯普胺和帕金森病药物、或钙通道阻滞剂和利尿剂)的处方药物配药数据。在三个单独的分析中,发出引发药物的配药信号表明,从第一次配药日期回溯 365 天,以确认第二治疗药物是在引发药物之后开始的。当第二治疗药物在引发治疗后 180 天内开始时,即认为存在处方级联。使用 t 检验或卡方检验(视情况而定)测试性别的处方级联差异。使用单变量(未调整)和多变量(调整)逻辑回归(根据年龄、农村和性别进行调整)和 Cox 比例风险回归来确定处方级联的危险因素。
从 2005 年 3 月 1 日至 2015 年 3 月 31 日,确定了 28953 名新斯科舍省老年人处方药计划有痴呆症(NSSPBD)的受益人。队列中有 60 例膀胱抗胆碱能药物继发于胆碱酯酶抑制剂,11 例帕金森病药物继发于甲氧氯普胺,289 例利尿剂继发于钙通道阻滞剂。回归分析表明,膀胱抗胆碱能药物继发于胆碱酯酶抑制剂和利尿剂继发于钙通道阻滞剂的风险与女性有关。Cox 回归表明,使用胆碱酯酶抑制剂的患者较少使用膀胱抗胆碱能药物,并且没有发现钙通道阻滞剂的使用更频繁地导致利尿剂的使用。
钙通道阻滞剂后联合使用利尿剂是最常见的处方级联,而胆碱酯酶抑制剂后联合使用膀胱抗胆碱能药物是第二常见的。然而,暴露于引发药物并没有增加暴露于第二治疗药物的风险。女性中,胆碱酯酶抑制剂后联合使用膀胱抗胆碱能药物和钙通道阻滞剂后联合使用利尿剂的情况更为常见,这表明女性可能面临更高的这些处方级联风险。